This was the stock's second consecutive day of losses.

The stock's fall snapped a two-day winning streak.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

Anne Wojcicki is taking back reins of 23andMe after outbidding Regeneron. The entrepreneur's proposal offers better ...

Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron ...

The S&P 500 added 0.6% on Tuesday, June 10, 2025, as investors awaited developments in the trade negotiations between the U.S ...

US Stock market future today is showing signs of caution as Dow, S&P 500, and Nasdaq futures hold steady during ongoing ...

US stock markets finished more or less flat on Monday, as investors took a breather with indices trading at their highest levels in nearly four months.

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...